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were no treatment-related deaths (i.e. within 90 days of 
treatment), and an acceptable short- and long-term safety 
profile. Physiological and clinical benefits were observed at 
24 weeks. Efficacy responses were better among Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD) stage III 
patients [n = 14; change in residual volume/total lung capac-
ity (  RV/TLC) = –7.4  8 10.3%;   forced expiratory volume in 
1 s (  FEV 1 ) = +15.9  8 22.6%; change in forced vital capacity 
(  FVC) = +24.1  8 22.7%; change in carbon monoxide lung 
diffusion capacity (  DL CO) = +19.3  8 34.8%; change in 6-min 
walk test (  6MWD) = +28.7  8 59.6 m; change in Medical Re-
search Council Dyspnea (  MRCD) score = –1.0  8 1.04 units; 
change in St. George’s Respiratory Questionnaire (  SGRQ) 
score = –9.9  8 15.3 units] than for GOLD stage IV patients 
 (n = 7;   RV/TLC = –0.5  8 6.4%;   FEV 1 = +2.3  8 12.3%;
  FVC = +2.6  8 21.1%;   DL CO = –2.8  8 17.2%;   6MWD = 
+28.3  8 58.4 m;   MRCD = 0.3  8 0.81 units;   SGRQ = –6.7 
 8 7.0 units).  Conclusions: ELS therapy shows promise for 
treating patients with advanced heterogeneous emphyse-
ma. Additional studies to assess responses in a larger cohort 
with a longer follow-up are warranted. 
 Copyright © 2011 S. Karger AG, Basel 
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 Abstract 
 Background: This report summarizes initial tests of an em-
physematous lung synthetic polymer sealant (ELS) designed 
to reduce lung volume in patients with advanced emphy-
sema.  Objectives: The primary study objective was to define 
a therapeutic strategy to optimize treatment safety and ef-
fectiveness.  Methods: ELS therapy was administered bron-
choscopically to 25 patients with heterogeneous emphy-
sema in an open-label, noncontrolled study at 6 centers in 
Germany. Treatment was performed initially at 2–4 subseg-
ments. After 12 weeks, patients were eligible for repeat ther-
apy to a total of 6 sites. Safety and efficacy were assessed 
after 6 months. Responses were evaluated in terms of chang-
es from baseline in lung physiology, functional capacity, and 
health-related quality of life. Follow-up is available for 21 of 
25 patients.  Results: Treatment was well tolerated. There 
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 Introduction 
 Bronchoscopic approaches to achieve lung volume re-
duction have recently been explored as safer alternatives 
to lung volume reduction surgery (LVRS) for treating ad-
vanced emphysema  [1, 2] . While these techniques are as-
sociated with less morbidity and mortality than LVRS, 
the majority have demonstrated limited effectiveness. 
Endobronchial valves, which are designed to obstruct the 
proximal airways and cause absorption atelectasis, have 
not consistently produced volume reduction, physiologi-
cal benefit or improvements in symptoms  [3–6] . Airway 
bypass therapy, developed for the treatment of homoge-
neous emphysema, has been associated with transient 
improvements in vital capacity and dyspnea, but the pro-
cedure is complex, and benefits have not been durable 
 [7–9] .
 A corporate-sponsored (Aeris Therapeutics, Woburn, 
Mass., USA) study on human subjects was recently com-
pleted. The study tested a synthetic polymer (emphyse-
matous lung sealant; ELS) designed to produce durable 
volume reduction by blocking up airways and collateral 
ventilation pathways, and sealing the collapsed region. It 
was designed as a noncontrolled, open-label, multicenter 
dose escalation study to identify the optimal treatment 
strategy. Approximately 24 patients were designated for 
enrollment in 3 treatment groups (n = 8 each). Because 
the dose required to achieve therapeutic benefit was un-
known at the start of the tests, all patients were offered 
retreatment after 12 weeks. Group 1 patients received ini-
tial therapy at 2 subsegments in 1 lobe, and were eligible 
for retreatment at 2–3 additional sites. Group 2 patients 
received initial therapy at 3 subsegments in 1 lobe, and 
were eligible for retreatment at 2–3 additional sites. Group 
3 patients received initial therapy at 4 subsegments in 1 
lobe, and were eligible for retreatment at 1–2 additional 
sites. Follow-up was performed at 12 and 24 weeks follow-
ing completion of therapy. This report summarizes re-
sponses through week 24 for 21 of 25 patients.
 Materials and Methods 
 Enrollment Criteria 
 All study participants had heterogeneous, upper lobe predom-
inant emphysema, respiratory symptoms despite American Tho-
racic Society (ATS)/European Respiratory Society (ERS) recom-
mended medical therapy, and were either not eligible for, or had 
refused, LVRS and lung transplantation. Study inclusion criteria 
required: (1) heterogeneous emphysema defined by CT imaging; 
(2) persistent symptoms [i.e. a baseline Medical Research Council 
Dyspnea (MRCD) score of  6 2] despite medical therapy; (3) age 
 1 40 years; (4) severe airflow limitation defined as a ratio of forced 
expiratory volume in 1 s (FEV 1 ) to forced vital capacity (FVC) 
 ! 70% and an FEV 1  ! 50% predicted; (5) hyperinflation [total lung 
capacity (TLC)  1 100% predicted and residual volume (RV)  1 135% 
predicted]; (6) absence of   1 -antiprotease deficiency; (7) absence 
of clinically significant pulmonary hypertension, defined as a 
pulmonary systolic pressure  1 45 mm Hg (by cardiac echo and/or 
right heart catheterization), and (8) abstinence from smoking for 
 6 4 months prior to enrollment. Patients determined to be at high 
risk of mortality for LVRS, with an FEV 1  ! 20% predicted and a 
carbon monoxide lung diffusion capacity (DL CO)  ! 20% predict-
ed, were also excluded from study participation  [10] .
 Study Conduct 
 Patients received ELS therapy at up to 6 target sites during ei-
ther a single treatment session or 2 treatment sessions. All par-
ticipating institutions contributed at least 1 patient.
 Fourteen patients had Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) stage III chronic obstructive pulmo-
nary disease (COPD) and 11 GOLD stage IV COPD. Eight pa-
tients (6 stage III and 2 stage IV) were enrolled in group 1, and 
received initial treatment at 2 subsegments in 1 lobe; 3 received a 
second treatment at 2 additional subsegments. Eight patients were 
enrolled in group 2 (3 stage III and 5 stage IV) and received initial 
treatment at 3 subsegments in 1 lobe; 2 received a second treat-
ment at 3 additional subsegments. Nine patients were enrolled in 
group 3 (5 stage III and 4 stage IV) and received initial treatment 
at 4 subsegments in 1 lobe; none underwent repeat therapy.
 The study protocol was reviewed and approved by the Bundes-
institut für Arzneimittel und Medizinprodukte (BfArM) via 
Deutsches Institut für Medizinische Dokumentation und Infor-
mation (DIMDI) and national and local ethics committees. All 
study participants reviewed and signed informed consent forms 
before enrolling.
 Screening evaluations included pulmonary function tests (spi-
rometry, plethysmography and single-breath diffusing capacity 
measurements), a 6-min walk test (6MWT), echocardiography, 
electrocardiography, chest CT scan performed at full inspiration, 
clinical pathology (hematology, coagulation studies, and serum 
chemistry measurements), a modified MRCD questionnaire, and 
a St. George’s Respiratory Questionnaire (SGRQ) health-related 
quality of life questionnaire. Pulmonary function tests were per-
formed according to published ATS/ERS guidelines. CT images 
were generated according to a standard acquisition/reconstruc-
tion algorithm (spiral acquisition using a multidetector CT scan-
ner with 1 mm collimation, a pitch of 1, and 0.5 mm overlap)  [11] .
 ELS treatments were performed in the endoscopy suite under 
general anesthesia (24 patients) or conscious sedation (1 patient) 
per investigator preference. All patients were admitted to the hos-
pital for observation following treatment.
 Outcome Measures 
 The primary endpoint of the study was RV/TLC ratio mea-
sured 3 months following final treatment. Efficacy was further 
assessed in terms of change from baseline at 3 and 6 months in 
postbronchodilator FEV 1 and FVC, DL CO , 6MWT distance, 
MRCD score, SGRQ health-related quality of life total domain 
score, and change from baseline in RV/TLC at 6 months.
 Safety was assessed in terms of the incidence of adverse events 
and serious adverse events throughout the study.
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 The ELS Procedure 
 Disease heterogeneity was assessed by each principal investi-
gator in conjunction with his or her consulting radiologist using 
CT images obtained at full lung inflation. Qualification for study 
participation was based solely on the subjective clinical CT assess-
ments of principal investigators and their staff. Additional quan-
titative CT analysis was performed by the sponsor’s medical staff 
using computerized algorithms (Pulmonary Workstation Plus 
Software, VIDA Diagnostics, Iowa City, Iowa, USA) for investiga-
tional purposes. All participants had upper lobe heterogeneous 
disease, and received treatment in the upper lobes or superior seg-
ments of the lower lobes.
 Therapy was administered with the bronchoscope in wedge 
position at the airway subsegment. ELS foam sealant was de-
livered through a single lumen catheter with its tip positioned 
2 cm beyond the bronchoscope. Wedge position was maintained 
throughout delivery to prevent backflow into the airway. The 
foam sealant was prepared at the bedside from aqueous polymer 
solution and cross-linker. Polymer solution contains 2% aminat-
ed polyvinylalcohol in phosphate buffer. Cross-linker consists of 
dilute, buffered pentane 1–5 dial. Cross-linker (0.5 ml) was added 
to the polymer substrate (4.5 ml) in a 20-ml syringe to initiate po-
lymerization, which proceeds over approximately 3 min. The 
5-ml solution was mixed with 15 ml of air to generate 20 ml of 
foam sealant by passing the material back and forth through a 
stopcock between the syringes 10 times. 20 ml of liquid foam seal-
ant was injected over 10–20 s. Wedge position was maintained for 
1 min following delivery to allow complete in situ polymerization. 
The scope was then repositioned at the next treatment site, and 
the procedure repeated until all treatments were completed.
 Polymer components are compatible with commercially avail-
able bronchoscopes. No special precautions were required in han-
dling or cleaning bronchoscopy equipment following treatment.
 Data Presentation and Statistical Analysis 
 Efficacy outcomes at 12 and 24 weeks after treatment are com-
pared with baseline values and reported as change from baseline. 
Statistical significance of the posttreatment change in primary 
endpoint (RV/TLC ratio at 12 weeks) was assessed by nonpara-
metric testing (Mann-Whitney test). A significant change was de-
fined as p  ! 0.05. Comparisons for secondary endpoints were per-
formed by nonparametric testing (Mann-Whitney) and statistical 
significance was based upon p values subject to correction for 
multiple comparisons using the method of Bonferroni. Correla-
tions between continuous variables were performed using the 
method of Pearson.
 Results 
 Patient Enrollment, Demographics, and Medical 
History 
 Seventeen of the 25 patients in this cohort were males. 
Ages ranged from 49 to 74 years (62.7  8 7.4, median 66). 
All patients were prior smokers (43.8  8 17.7 pack-years, 
median 38 pack-years years). Nine patients were oxygen 
dependent. None were wheelchair bound or used nonin-
vasive ventilator support.
 Eleven patients were receiving short-acting inhaled   -
agonists, 7 short-acting anticholinergics, 17 long-acting 
inhaled   -agonists, 19 long-acting anticholinergics, and 
18 inhaled steroids. Six patients used theophylline prepa-
rations and 4 oral corticosteroids. One patient was listed 
for lung transplantation. Three had previously under-
gone endobronchial lung volume reduction procedures: 1 
patient had received ablative vapor therapy 8 months pri-
or to ELS therapy; 1 had undergone valve placement and 
subsequent removal 24 months before; 1 had undergone 
valve placement and subsequent removal 9 months be-
fore. Baseline physiology and functional characteristics 
of study participants are summarized in  table 1 .
 Safety Results 
 Procedural Safety 
 All patients tolerated the ELS procedure without sig-
nificant problems. There were no serious procedural or 
immediate postprocedural complications. Specifically, 
there were no episodes of bleeding, pneumothorax, respi-
ratory failure requiring ventilator support, instances in 
Table 1. B aseline physiology and functional assessments of study participants
Entire cohort (n = 25) GOLD stage III (n = 14) GOLD stage IV (n = 11)
FEV1, liters 0.9280.28 (30.187.7) 1.0980.21 (35.484.3) 0.6780.18 (22.284.2)
FVC, liters 2.4480.64 (60.0812.3) 2.5980.55 (63.4811.3) 2.2180.69 (54.8812.3)
RV, liters 5.8181.09 (257.9853.0) 5.3780.89 (229.2843.1) 6.4781.01 (301.1833.5)
TLC, liters 8.4481.24 (136.7819.6) 8.1880.99 (128.8819.0) 8.8381.45 (148.6814.4)
DLCO, mmol/min/kPa 2.2081.21 (25.8811.2) 2.6381.22 (29.9811.5) 1.5280.78 (18.385.7)
MRCD, units 2.7680.78 2.6780.72 2.9080.88
6MWD, m 293.6883.9 324.6884.8 247.1859.9
Results in parentheses are percentages of predicted.
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which conscious sedation had to be converted to general 
anesthesia or instances where the procedure was aborted 
because of clinical instability. Three patients experienced 
spillage of material from the administration site into the 
central airways. In all 3 instances, the material was cleared 
by suctioning through the bronchoscope without conse-
quence. The average procedure time to complete treatment 
was 19.7  8 8.6 min (median 18.1 min), and the duration 
of each treatment was 6.9  8 2.4 min (median 7.3 min).
 Posttreatment Complications Associated with ELS 
Therapy 
 ELS treatment was routinely associated with a ‘flu-
like’ reaction beginning 8–24 h following treatment. All 
patients treated with ELS experienced some component 
of this reaction. The most common side effects were ele-
vated inflammatory markers (sedimentation rate and/or 
C-reactive protein; n = 25), dyspnea (n = 25), fever (n = 
22), leukocytosis (n = 21), infiltrate on chest radiograph 
(n = 16), and chest pain (n = 12). Symptoms were gener-
ally self-limited and resolved within 24–96 h with sup-
portive care. Symptoms lasting more than 24 h were 
treated with a combination of nonsteroidal anti-inflam-
matory medications, acetaminophen, corticosteroids, 
and additional supportive care (i.e. bronchodilators, an-
tibiotics) as indicated. Leukocytosis and elevated inflam-
matory indices resolved within 3–7 days.
 There were no treatment-related deaths (defined as a 
death within 90 days of treatment), episodes of treatment-
related respiratory failure requiring ventilator support of 
 1 24 h duration, pneumothoraces, empyemas, lung ab-
scesses, pulmonary emboli, episodes of heart failure, car-
diac ischemia or myocardial infarction, or cardiac ar-
rhythmia requiring medical treatment during follow-up.
 Among the 14 patients with GOLD stage III emphy-
sema, there were 6 COPD exacerbations, 4 of which were 
treatment related. One was an acute posttreatment exac-
erbation (day 6 after treatment), that resulted in prolon-
gation of initial hospitalization, 3 were subacute (days 34, 
37 and 51 after treatment), and 2 were subchronic (days 
89 and 110 after treatment). All were medically signifi-
cant and required hospitalization and treatment with 
corticosteroids and antibiotics. One GOLD stage III pa-
tient experienced pneumonia 61 days after treatment at a 
nontreatment site that required inpatient medical ther-
apy. One GOLD stage III patient experienced a clinical-
ly significant decline in pulmonary lung function (i.e. 
  FEV 1 = –17% from baseline) at 24 weeks’ follow-up.
 Among the 11 patients with GOLD stage IV COPD, 
there were 4 COPD exacerbations requiring hospitaliza-
tion, all treatment related. Two occurred in the periproce-
dural period on days 5 and 11, and 2 were subacute, pre-
senting on days 34 and 37 after the procedure. One event 
required supplemental oxygen and admission to the inten-
sive care unit. Two additional patients presented with non-
treatment-related respiratory failure (days 116 and 159 fol-
lowing treatment) requiring hospitalization and intensive 
care support. There were 2 pneumonias (days 1 and 45 af-
ter treatment) both of which required hospitalization and 
resolved with treatment. One patient developed acute coli-
tis 27 days following treatment that required surgical in-
tervention and another sustained clinically significant de-
pression 71 days after treatment that required hospitaliza-
tion and medical intervention. One patient presented with 
mild hemoptysis 284 days following treatment, which re-
solved spontaneously. One patient with GOLD stage IV 
disease experienced a clinically significant (–12%) decline 
in FEV 1 from baseline at 24 weeks’ follow-up.
 Efficacy Results 
 Efficacy responses are summarized in  figure 1 and in 
 tables 2–4 for: (a) the entire cohort ( fig.  1 ;  table  2 ); (b) 
GOLD stage III patients ( table 3 ), and (c) GOLD stage IV 
patients ( table 4 ). Wherever possible, published minimal 
clinically important difference (MCID) criteria as set 
forth by the ERS/ATS Standards Committee were applied 
to define the number of patients achieving a clinically 
significant response to therapy  [12] .
 Figure 1 and  table 2 summarize results for the entire 
cohort. Mean improvements at 12 weeks’ follow-up were 
observed in spirometry (  FEV 1 = +7.9  8 19.1%; p = 0.07 
and   FVC = +6.6  8 23.7%; p = 0.21), gas trapping (  RV/
TLC = –3.4  8 9.2%; p = 0.09), symptoms (  MRCD = –0.5 
 8 1.21 units; p = 0.06), quality of life (  SGRQ total do-
main score = –7.1  8 14.2 units; p = 0.05), and exercise 
capacity (  6MWD = +35.6  8 66.7 m; p = 0.02), although 
none reached statistical significance following correction 
for multiple comparisons. Improvements from baseline 
for most outcome measures at 24 weeks were greater than 
at 12 weeks:   FEV 1 = +10.0  8 19.8% (p = 0.03),   FVC = 
+15.86.6  8 22.2% (p = 0.004),   RV/TLC = –4.7  8 9.5% 
(p = 0.04),   MRCD = –0.4  8 1.20 units (p = 0.16),   SGRQ 
total domain score = –7.5  8 14.4 units (p = 0.05), and 
  6MWD = +24.6  8 58.9 m; p = 0.08. Only the improve-
ment in FVC was statistically significant when corrected 
for multiple comparisons.
 Table  3 summarizes  efficacy responses among pa-
tients with GOLD stage III COPD (n = 14). ELS therapy 
was associated with a statistically significant change from 
baseline in the study primary endpoint, RV/TLC ratio at 
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 Fig. 1. Histograms showing response patterns 6 months following ELS therapy for those outcome measures with 
MCID criteria defining a clinically significant improvement. Criteria applied here are as follows:   FEV  6 10%; 
  FVC  6 10%;   6MWD  1 50 m;   MRCD reduction  1 1 unit;   SGRQ reduction  1 8 units. 
Table 2. E fficacy responses at 12 and 24 weeks’ follow-up for GOLD stage III + IV patients
12 weeks (n = 21) 2 4 weeks (n = 21)
change from baseline responders p chan ge from baseline responders p
FEV1, liters 0.07080.193 
 (7.9819.1%)
41% 0.067 0.10580.201
 (10.0819.8%)
43% 0.028
FVC, liters 0.11680.577 
 (6.6823.7%)
41% 0.207 0.38080.523  
 (15.8822.2%)
55% 0.004*
RV/TLC, % –3.489.2 NA 0.092 –4.789.5 NA 0.039
DLCO, mmol/min/kPa –0.03680.571
(–2.7829.1%)
NA 0.695 0.29780.696
(14.4833.0%)
NA 0.081
MRCD, units –0.581.21 33% 0.063 –0.481.20 47% 0.161
6MWD, m 35.6866.7 38% 0.021 24.6858.9 38% 0.078
SGRQ, units –7.1814.2 50% 0.049 –7.5814.4 47% 0.049
Res ponder criteria defined as follows: FEV1 ≥+15%; FVC ≥+15%; MRCD ≤–1 unit; 6MWD ≥50 m; SGRQ ≤–8 units; NA = 
established MCID criteria do  not exist. p values calculated compared to baseline. * Denotes statistically significant change from base-
line when corrected for multiple comparisons.
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3 months’ follow-up (–5.4  8 8.6%, p = 0.035). Mean 
 improvements in secondary efficacy outcome measures 
were observed at 3 and 6 months. Improvements from 
baseline at 3 months were observed in FEV 1 (  = +9.1  8 
20.6%, p = 0.131), FVC (  = +13.6  8 20.6%, p = 0.057), 
DL CO (  = +6.1  8 26.6%, p = 0.247), 6MWD (  = +41.3 
 8 74.8 m, p = 0.064), MRCD (  = –1.0  8 1.18 units, p = 
0.007) and SGRQ total domain score (  = –7.9  8 15.7 
units, p = 0.105). Improvements at 6 months were ob-
served in FEV 1 (  = +15.9  8 22.6%, p = 0.048), FVC 
(   = +24.1  8 22.7%, p = 0.010), RV/TLC (  = –7.4  8 
10.3%, p = 0.031), DL CO (  = 14.6  8 27.1%, p = 0.053), 
6MWD (  = +28.7  8 59.6 m, p = 0.106), MRCD (  = –1.0 
 8 1.04 units, p = 0.013) and SGRQ total domain scores 
(  = –9.9  8 15.3 units, p = 0.048). Only the improvement 
in FVC was statistically significant when corrected for 
multiple comparisons.
 Table 4 summarizes efficacy responses among patients 
with GOLD stage IV COPD (n = 7). Mean improvements 
for all efficacy outcome measures in stage IV COPD pa-
tients were smaller and more variable than those of stage 
III patients.
Table 3. E fficacy responses at 12 and 24 weeks’ follow-up for GOLD stage III patients
12 weeks (n = 14) 2 4 weeks (n = 14)
change from baseline responders p change from ba seline responders p
FEV1, liters 0.09880.223 
   (9.1820.6%)
36% 0.131 0.13480.225
 (15.9822.6%)
50% 0.048
FVC, liters 0.27780.492
 (13.6820.6%)
50% 0.057 0.49580.465
 (24.1822.7%)
64% 0.010
RV/TLC, % –5.488.6 NA 0.035* –7.4810.3 NA 0.031
DLCO, mmol/min/kPa 0.05380.582 
(6.1826.6%)
NA 0.247 0.34780.744
(19.3834.8%)
NA 0.059
MRCD, units –1.081.18 57% 0.007 –1.081.04 71% 0.013
6MWD, m 41.3874.8 57% 0.064 28.7859.6 36% 0.106
SGRQ, units –7.9815.7 50% 0.105 –9.9815.3 67% 0.048
Res ponder criteria defined as follows: FEV1 ≥+15%; FVC ≥+15%; MRCD ≤–1 unit; 6MWD ≥50 m; SGRQ ≤–8 units; NA = 
established MCID criteria do not exist. p values calculated compared to baseline. * Denotes statistically significant change from base-
line.
Table 4. E fficacy responses at 12 and 24 weeks’ follow-up for GOLD stage IV patients
12 weeks (n = 8) 2 4 weeks (n = 7)
change from baseline responders p change f rom baseline responders p
FEV1, liters 0.01180.090
(5.4816.1%)
50% 0.347 0.03280.105
(2.3812.3%)
43% 0.611
FVC, liters –0.07280.527
(–2.1827.6%)
50% 0.827 0.03480.589
(2.6821.1%)
43% 0.736
RV/TLC, % –0.388.5 NA 0.792 –0.586.4 NA 0.674
DLCO, mmol/min/kPa –0.48080.211
(–17.4813.9%)
NA 0.067 0.04680.357
(–2.8817.2%)
NA 0.789
MRCD, units 0.081.31 13% 0.981 0.380.81 14% 0.363
6MWD, m 28.4855.7 25% 0.193 28.3858.4 43% 0.288
SGRQ, units –7.089.5 38% 0.099 –6.787.0 29% 0.048
Res ponder criteria defined as follows: FEV1 ≥+15%; FVC ≥+15%; MRCD ≤–1 unit; 6MWD ≥50 m; SGRQ ≤–8 units; NA = 
established MCID criteria do not exist. p values calculated compared to baseline.
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 Radiologic Results 
 CT imaging was performed at baseline and 12 weeks 
after treatment to characterize the anatomic response to 
ELS therapy and the extent of lobar volume reduction at 
the sites of treatment. Baseline CT images confirmed 
the presence of moderate to severe heterogeneous em-
physema. Parenchymal damage, characterized in terms 
of tissue density (Hounsfield units, HU) was as follows: 
(1) mean tissue density of both lungs = –894  8 17 HU; 
(2) percentage of tissue less than –950 HU in the upper 
lung fields (right upper lobe + left upper lobe/2) = 52  8 
10%; (3) percentage of tissue less than –950 HU in the 
lower lung fields (right lower lobe + left lower lobe/2) = 
39  8 12%,  and  (4)  the  ratio  of  disease    ! –950   HU   in 
the   upper divided by lower lung field (%  ! –950 up-
per/–950 lower) = 1.49  8 0.72. Reduction in lobar vol-
ume at 12 weeks’ follow-up, expressed as decrease in gas 
volume per subsegment treated from analysis of CT im-
ages generated at full lung inflation, was 188  8 151 ml/
site [only 20 CT scans (14 GOLD stage III patients and 
6 GOLD stage IV patients) were appropriately formatted 
to allow lobar volume assessments at 12-week follow-
up].
 Representative CT images of patients treated at 2, 3 or 
4 subsegmental sites are shown in  figure 2 . Regional vol-
ume loss was observed at every treatment site across the 
cohort. ELS therapy was not associated with radiologic 
changes outside of treatment sites. There was no evi-
dence of treatment-related mediastinal or pleural pathol-
ogy.
Baseline, 2 sites
12 weeks, 2 sites
3 sites
3 sites
4 sites
4 sites
 Fig. 2. Coronal CT images at baseline (top) and 12 weeks after ELS treatment (bottom) after 2-, 3- and 4-site 
therapy. 
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 Correlation between Changes in Primary and 
Secondary Outcome Measures 
 To assess the relationship between changes in gas trap-
ping and changes in spirometry, gas exchange, symp-
toms, and quality of life following ELS therapy, %  RV/
TLC from baseline was correlated with changes in FEV 1 , 
FVC, DL CO , 6MWD, MRCD, and SGRQ at 6 months’ fol-
low-up. Results, summarized in  figure 3 , show statisti-
cally significant correlations between reduction in RV/
TLC at 6 months, and improvements in FEV 1 (r = –0.759, 
p  ! 0.001), FVC (r = –0.703, p  ! 0.001), DL CO (r = –0.619, 
p = 0.012), and SGRQ total domain score (r = 0.481, p = 
0.05).
 Discussion 
 ESL (AeriSeal  System therapy) is a novel, minimally 
invasive alternative to LVRS being evaluated for treat-
ment of patients with advanced emphysema. It appears to 
function by blocking small airways and collateral ventila-
tion pathways, which leads to absorption atelectasis  [13] . 
Results of this study indicate that ELS treatment can be 
performed safely in patients with advanced emphysema, 
and can reduce gas trapping and improve FEV 1 , FVC, 
DL CO and quality of life up to 6 months in appropriately 
selected patients  [14, 15] .
 Treatments were generally well tolerated, and did not 
require special equipment or fluoroscopy. Treatment 
times averaged approximately 7 min per site. Acute side 
effects consisted of an inflammatory ‘flu-like’ reaction 
that was observed in all patients, but was generally mild 
and responded to supportive medical care. Inflammatory 
reactions were, however, more pronounced in patients 
treated at 4 sites during a single session, and some pa-
tients in this cohort required additional supportive care 
and experienced longer hospitalizations than those treat-
ed at 2 and 3 sites.
 There were no treatment-related deaths during the 
study. The most common serious complication associat-
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 Fig. 3. Correlations between change in gas trapping and secondary outcome measures at 24 weeks. Correlations 
between   RV/TLC and secondary outcome measures 24 weeks following treatment for the entire cohort. Re-
sults show that changes in gas trapping correlated more closely with improvements in objective physiological 
outcome measures such as spirometry and diffusing capacity than with subjective outcome measures such as 
symptoms of dyspnea and quality of life. 
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ed with ELS therapy was COPD exacerbation. Three peri-
procedural (with the first week of treatment), and 7 sub-
acute (between post-treatment days 8 and 90) exacer-
bations were reported; the majority (8) were treatment 
related. The incidence of COPD exacerbations reported 
here is similar to that observed with other endobronchial 
lung volume reduction methods  [5, 16, 17] . Late treat-
ment-related complications ( 1 90 days after treatment), 
and evidence of sensitization following ELS treatment, 
such as eosinophilia, skin rash, or rhinitis were not ob-
served.
 Results show that ELS treatment reduces gas trapping, 
which correlates with improvements in pulmonary func-
tion, exercise capacity and quality of life. CT analysis in-
dicates that ELS treatment causes local atelectasis at sites 
of treatment with reductions in gas volume at full lung 
inflation of approximately 190 ml per treatment site. 
Overall responses at 12 and 24 weeks are similar to those 
previously reported following unilateral LVRS  [18–21] . 
Physiological improvements following ELS therapy were 
greater in patients with GOLD stage III disease than stage 
IV disease. This is not unexpected given that stage IV pa-
tients had lower baseline spirometry (% predicted FEV 1 
of 22.2  8 4.2 vs. 35.4  8 4.3; p  ! 0.001) and DL CO (% pre-
dicted DL CO of 18.3  8 5.7 vs. 29.9  8 11.5; p  ! 0.001), and 
greater hyperinflation (% predicted RV of 301  8 34 vs. 
229  8 43; p  ! 0.001). These differences likely reflect more 
extensive tissue destruction and airway disease among 
the GOLD stage IV patients enrolled in this trial. Given 
the apparent mechanism of action of ELS, it is likely that 
for  stage  IV  patients,  additional  volume reduction will 
be required to produce improvements in lung function 
equivalent to stage III patients.
 Five patients underwent repeat ELS therapy in this 
study. Second sessions were well tolerated with no evi-
dence of an exaggerated inflammatory reaction or aller-
gic response. Additional clinical benefit, beyond that 
achieved with initial treatment, was observed in 2 of 5 
patients. No patient experienced a decline in function fol-
lowing the second treatment session.
 Among study patients (n = 3) who had received prior 
endobronchial volume reduction therapy (vapor ablation 
therapy in 1 patient, endobronchial valve therapy with 
subsequent valve removal in 2 patients), responses were 
variable. ELS therapy was associated with improved spi-
rometry (  FEV 1 = +10.4% and +21.7%;   FVC = +10.5% 
and +30.8%), gas trapping (  RV/TLC = –2.5% and –8.4%), 
and quality of life (  SGRQ total domain score = –9.8 
units and –17.2 units) in 2 patients (1 previously treated 
with vapor ablation, 1 previously treated with valves). The 
third patient, who had developed airway scarring and 
partial lobar collapse from prior valve treatment, wors-
ened following ELS therapy (  FEV 1 = –17.4%;   FVC = 
–11.5%;   RV/TLC = +6.8%;   SGRQ total domain score = 
+25.8 units). Thus, the potential utility of ELS therapy for 
patients who have failed prior endobronchial volume re-
duction therapy remains unclear.
 While these initial results are encouraging, ELS ther-
apy, in contrast to endobronchial valves, is not reversible. 
Thus selection of patient and target sites using guidelines 
similar to those for identifying LVRS candidates is neces-
sary. Common indications for valve removal include air-
way complications associated with granulation tissue for-
mation and bleeding, and postobstructive infections. Al-
though complications of this type were not observed in 
this study, additional follow-up is needed in a larger co-
hort to fully assess whether irreversibility of treatment 
represents an important limitation of ELS therapy.
 In summary, ELS therapy is a novel endobronchial 
system that utilizes a synthetic polymeric tissue sealant 
to produce volume reduction for treating lung hyperin-
flation in advanced emphysema. While this study is too 
small to draw final conclusions about safety and effec-
tiveness, initial results using ELS are promising and sup-
port additional testing.
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